← Browse by Condition
Medical Condition

endocrine system diseases

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for endocrine system diseases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — endocrine system diseases Clinical Trials

How many clinical trials are currently recruiting for endocrine system diseases?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for endocrine system diseases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for endocrine system diseases?
endocrine system diseases research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a endocrine system diseases clinical trial?
Eligibility criteria for endocrine system diseases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Sociedad Española de Medicina Nuclear e Imagen Molecular 1 trial
University of Washington 1 trial
Eli Lilly and Company 1 trial

Recruiting Clinical Trials

NCT04949282
Recruiting
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Enrollment
5,000 pts
Location
Spain
Sponsor
Sociedad Española de Medicina ...
View Trial →
NCT07699380 Phase 2
Recruiting
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
Enrollment
60 pts
Location
United States, Nethe...
Sponsor
University of Washington
View Trial →
NCT07613307 Phase 3
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Enrollment
130 pts
Location
India, Saudi Arabia,...
Sponsor
Eli Lilly and Company
View Trial →

Related Conditions

glucose metabolism disorders (2) nutritional and metabolic diseases (2) neuroendocrine tumors (1) intestinal neoplasms (1) pancreatic neoplasms (1) stomach neoplasms (1) neuroectodermal tumors (1) neoplasms germ cell and embryonal (1) neoplasms by histologic type (1) neoplasms (1) neoplasms nerve tissue (1) gastrointestinal neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology